Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda To Create Wholly Owned Sales Units In Four Countries

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical says it plans to create sales and marketing units in four countries by the end of October. The firm said Belgium, Mexico, Sweden and Turkey are to be the new locations for Takeda wholly owned subsidiaries. The units are to sell the range of Takeda products, including its Actos (pioglitazone) drug for treating diabetes. (Click here for more - a subscription may be required

You may also be interested in...

Turkey's Changing Pharma Market Scene: What Opportunities For MNC Drug Makers?

Situated in one of the globe's most active emerging markets, the Turkish pharmaceutical industry is undergoing fast changes, which could make or break major drug makers, according to Istanbul-based international consulting firm Egon Zehnder International

QUOTED. 27 February 2020. Michael Gibson.

Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.

Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts